News & Views | Published:

Cancer drugs to treat birth defects

Nature Genetics volume 39, pages 10571059 (2007) | Download Citation

Subjects

Identical mutations of the same genes can lead either to congenital malformations or to cancer, depending on their cellular and temporal context. The demonstration of activated RAS-ERK signaling in a mouse model of Apert syndrome suggests that drugs designed to inhibit this pathway in cancer may also delay the progression of several serious pediatric syndromes.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , , , & Nat. Genet. 39, 1145–1150 (2007).

  2. 2.

    et al. Nat. Genet. 9, 165–172 (1995).

  3. 3.

    et al. Hum. Mol. Genet. 13, 2313–2324 (2004).

  4. 4.

    et al. Oncogene advance online publication 21 May 2007 (doi: 10.1038/sj.onc.1210529).

  5. 5.

    , , , & Bone 33, 169–178 (2003).

  6. 6.

    et al. Development 132, 3537–3548 (2005).

  7. 7.

    & Nat. Rev. Genet. 8, 173–184 (2007).

  8. 8.

    , , & Cytokine Growth Factor Rev. 16, 233–247 (2005).

  9. 9.

    Cytokine Growth Factor Rev. 16, 187–203 (2005).

  10. 10.

    et al. Proc. Natl. Acad. Sci. USA 103, 18603–18608 (2006).

  11. 11.

    , , , & Neurosurgery 59, 210–215 (2006).

  12. 12.

    et al. Nat. Struct. Mol. Biol. 11, 1192–1197 (2004).

  13. 13.

    & Ann. Med. 38, 200–211 (2006).

  14. 14.

    , & Nat. Rev. Cancer 7, 295–308 (2007).

  15. 15.

    et al. Nature 439, 358–362 (2006).

Download references

Author information

Affiliations

  1. Andrew O.M. Wilkie is at the Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. awilkie@hammer.imm.ox.ac.uk

    • Andrew O M Wilkie

Authors

  1. Search for Andrew O M Wilkie in:

Competing interests

The author declares no competing financial interests.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/ng0907-1057

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing